Anti-CD109/ CPAMD7/ p180 monoclonal antibody

Anti-CD109/ CPAMD7/ p180 antibody for FACS & in-vivo assay

Target products collectionGo to CD109/CD109 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)

pdfMSDSpdfCOApdfDatasheet

Product information

Catalog No.Product NameSpecies Reactivity
GM-Tg-hg-MP0193-Ab-1/ GM-Tg-hg-MP0193-Ab-2Anti-Human CD109 monoclonal antibodyHuman
GM-Tg-rg-MP0193-Ab-1/ GM-Tg-rg-MP0193-Ab-2Anti-Rat CD109 monoclonal antibodyRat
GM-Tg-mg-MP0193-Ab-1/ GM-Tg-mg-MP0193-Ab-2Anti-Mouse CD109 monoclonal antibodyMouse
GM-Tg-cynog-MP0193-Ab-1/ GM-Tg-cynog-MP0193-Ab-2Anti-Cynomolgus/ Rhesus macaque CD109 monoclonal antibodyCynomolgus/ Rhesus macaque
GM-Tg-felg-MP0193-Ab-1/ GM-Tg-felg-MP0193-Ab-2Anti-Feline CD109 monoclonal antibodyFeline
GM-Tg-cang-MP0193-Ab-1/ GM-Tg-cang-MP0193-Ab-2Anti-Canine CD109 monoclonal antibodyCanine
GM-Tg-bovg-MP0193-Ab-1/ GM-Tg-bovg-MP0193-Ab-2Anti-Bovine CD109 monoclonal antibodyBovine
GM-Tg-equg-MP0193-Ab-1/ GM-Tg-equg-MP0193-Ab-2Anti-Equine CD109 monoclonal antibodyEquine

Size： 1mg | 10mg | 100mg



Product Description

Catalog No.GM-Tg-hg-MP0193-Ab-1/ GM-Tg-hg-MP0193-Ab-2; GM-Tg-rg-MP0193-Ab-1/ GM-Tg-rg-MP0193-Ab-2;
GM-Tg-mg-MP0193-Ab-1/ GM-Tg-mg-MP0193-Ab-2; GM-Tg-cynog-MP0193-Ab-1/ GM-Tg-cynog-MP0193-Ab-2;
GM-Tg-felg-MP0193-Ab-1/ GM-Tg-felg-MP0193-Ab-2; GM-Tg-cang-MP0193-Ab-1/ GM-Tg-cang-MP0193-Ab-2;
GM-Tg-bovg-MP0193-Ab-1/ GM-Tg-bovg-MP0193-Ab-2; GM-Tg-equg-MP0193-Ab-1/ GM-Tg-equg-MP0193-Ab-2
Products NameAnti-CD109 monoclonal antibody
Formatmab
Target NameCD109
Protein Sub-locationTransmembrane Protein
Category of antibodyFACS/Biofunctional Antibody, Cytokine antibody
Derivation (species)Mouse
CH1+2+3 Isotype
(Receptor identification)		IgG
Type of Light Chain (VD-LC)N/A
Expression platformMammalian Expression
Bioactivity validationBinding affinity is validated by using flow cytometry with antigen overexpressed cell line. The biofunction of antibodies are validated in cell-based assay (IC50 or EC50 TBD).
TagFc
Products descriptionPre-made anti-CD109 benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS,ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic)
Purity Purity: ≥95% (SDS-PAGE)
Application Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation Lyophilized from sterile PBS, PH 7.4
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Associated products


    CategoryCat No.Products Name
    Target AntigenProducts DevelopingMulti-species CD109/ CPAMD7/ p180 VLP (virus-like particle) (Products Developing)
    CytokineGM-Tg-g-MP0193-Ag-1CD109 molecule (CD109) protein


    Target information

    Target IDGM-MP0193
    Target NameCD109
    Gene ID135228,235505,363104,716136,474970,101098303,534043,100068163
    Gene Symbol and Synonyms9930012E15Rik,CD109,CPAMD7,GARP,p180,r150
    Uniprot AccessionQ6YHK3
    Uniprot Entry NameCD109_HUMAN
    Protein Sub-locationTransmembrane Protein
    CategoryCytokine Target
    DiseaseN/A
    Gene EnsemblENSG00000156535
    Target ClassificationN/A

    The target: CD109, gene name: CD109, also named as CPAMD7, p180, r150. This gene encodes a glycosyl phosphatidylinositol (GPI)-linked glycoprotein that localizes to the surface of platelets, activated T-cells, and endothelial cells. The protein binds to and negatively regulates signalling by transforming growth factor beta (TGF-beta). Multiple transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Apr 2014].



    About Gmab

    GDU
    GDU



    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.

    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.